drug_type
RELEVANT_DRUG
intervention_type
oncolytic biologic (intratumoral)
drug_description
An intratumoral oncolytic biologic composed of recombinant, nonreplicating, noninfectious bacterial minicells; designed to directly lyse tumor cells upon injection, increasing local tumor antigen release and inflammation.
nci_thesaurus_concept_id
C170742
nci_thesaurus_preferred_term
Recombinant Bacterial Minicells VAX014
nci_thesaurus_definition
A population of recombinant bacterial minicells (rBMCs) engineered to express the alpha3beta1 (a3b1) and alpha5beta1 (a5b1) integrin-targeting invasion and that contain a bacterial protein toxin, perfringolysin O (PFO), with potential antineoplastic activity. Upon intravesical administration, VAX014 selectively targets and binds to tumor cells expressing un-ligated a3b1 and/or a5b1 integrins and delivers PFO, leading to destabilization of tumor cell membranes and tumor cell lysis. By targeting un-ligated a3b1 and/or a5b1 integrins, VAX014 selectively targets tumor cells over normal cells, with potentially less adverse effects in comparison with first generation integrin-targeted therapies.
drug_category
ONCOLYTIC VIRUS
drug_class
Other treatment
drug_delivery_route
Intratumoral
drug_mechanism_of_action
Recombinant, nonreplicating bacterial minicells engineered to target un-ligated a3b1/a5b1 integrins on tumor cells deliver the pore-forming toxin perfringolysin O, causing membrane disruption and rapid tumor cell lysis after intratumoral injection. The resulting oncolysis increases local tumor antigen release and inflammation, which can enhance antitumor immunity and synergize with PD-1 blockade.
drug_name
VAX014
nct_id_drug_ref
NCT05901285